Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors

作     者：Sun Tieying Sun Li Wang Rongmei Ren Xiaoping Sui Dong-jiang Pu Chun Ren Yajuan Liu Ying Yang Zhuo Li Fengzhi 

作者机构：Department of Respiratory and Critical Care Medicine Beijing Hospital of the Ministry of Health Beijing 100730 China Department of Respiratory Diseases Shaanxi Provincial People's Hospital Xi'an Shaanxi 710068China Department of Respiratory Diseases Air Force General HospitalPeople's Liberation Army Beijing 100142 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2014年第127卷第7期

页      面：1201-1205页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：pneumonia community-acquired infection moxifloxacin levofloxacin metronidazole 

摘      要：Background Community-acquired pneumonia （CAP） is a common infectious disease throughout the world and the incidence continues to grow as the population *** is an important pathogenic mechanism for pneumonia in the elderly and the management of patients with community-acquired pneumonia with aspiration factors is a major medical *** study aimed to assess whether moxifloxacin in comparison to levofloxacin plus metronidazole are effective and safe in the treatment of community-acquired pneumonia with aspiration *** In this prospective,multicenter,open-label,randomized controlled trial,77 patients with mild-to-moderate community-acquired pneumonia with aspiration factors were enrolled and randomly assigned to receive moxifloxacin or levofloxacin plus *** primary efficacy variables were clinical outcomes in evaluable patients at a follow-up visit 7 to 14 days after the end of *** Seven days after the end of therapy a clinical cure was achieved for 76.7％ （23 of 37） of efficacy-evaluable patients in the moxifloxacin group and 51.7％ （15 of 40） of patients in the levofloxacin plus metronidazole *** was a significant difference between the two groups （x2=4.002,P 0.05）.Bacteriological success rates were similar in the moxifloxacin group （93.3％） and levofloxacin plus metronidazole group （96.4％）,there was no significant difference between the two groups （P 0.05）.The overall adverse event rate was 10.8％ （4/37） in the moxifloxacin group versus 17.5％ （7/40） in the levofloxacin plus metronidazole group,there was no significant difference between the two groups （P0.05）.No serious adverse events were *** Moxifloxacin is effective and safe for treatment of community-acquired pneumonia with aspiration *** the regimen of moxifloxacin monotherapy is more convenient compared with levofloxacin plus metronidazole.